SIGMA-SYSTEMS
2.5.2017 11:02:08 CEST | Business Wire | Press release
Sigma Systems, a global leader in catalog-driven software, has appointed Catherine Michel as Chief Technology Officer (CTO).
Michel previously served as Chief Strategy Officer (CSO) on Sigma’s leadership team, and currently sits on the TM Forum Executive Committee, has been named as one of the most powerful people in the telecoms industry by Global Telecoms Business, and is a public advocate and mentor for women in telco and IT. As Sigma’s Chief Technology Officer, Catherine is responsible for the company's product portfolio and strategy.
“Catherine is a globally respected member of the IT and communications technology community, and we are very fortunate to have her on the Sigma team. She has an excellent track record of innovation within the software development arena and is a highly strategic thinker. Catherine has been vital in driving Sigma’s product portfolio forward, and will continue to do so in her new role in the coming months and years. Catherine is a key spokesperson for the company at events and technology forums across the globe,” said Tim Spencer, Sigma’s President and CEO.
Prior to her roles at Sigma, Michel was the founder and CTO of Tribold, where she was the principal architect of the company's products and solutions portfolio. Tribold was acquired by Sigma in 2013. Prior to co-founding Tribold, she was a senior executive in Accenture's Communications and High Tech practice, devising and delivering business strategy and large-scale B/OSS solutions globally.
“Sigma is on the cutting edge of delivering technology solutions that enable operators to truly transform into agile digital service providers,” observed Michel. “I continue to be excited about the position we’ve achieved in the market and the opportunities ahead of us.”
Catherine will be speaking at TM Forum Live! in Nice with Sigma customer Windstream. The joint presentation will outline how Windstream developed, governed and executed a widespread digital transformation program in parallel with a major acquisition and SDN deployment. As a key strategic partner, Sigma is supporting Windstream’s transition to an agile delivery organization with the adoption of catalog-driven Agile B/OSS. Sigma’s portfolio is designed to support CSPs like Windstream to embrace digital innovation and enable the rapid launch and fulfilment of new products and services without entirely dismantling existing legacy systems.
Presentation Details:
May 15th
, 11:15am
TM Forum
Live!
Palais des Congrès Acropolis, Nice, France
About Sigma Systems (
sigma-systems.com
or Twitter @SigmaSystems)
Sigma Systems is a global leader in
catalog-driven software solutions for communications, media, and
high-tech companies. It serves over 80 customers in 40 countries with
its award-winning products.
The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management and Provisioning products, which can be deployed in the cloud or on-premise. Sigma utilizes an agile approach to implementing its B/OSS products for its customers.
Sigma has offices in North and South America, Europe and Asia, with technology and integration partners in over 100 countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005185/en/
Contact:
Sigma Systems
Noor Manji, 416-943-9696
Manager, Corporate
Communications
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom